Literature DB >> 18425412

Myostatin as a therapeutic target for musculoskeletal disease.

L Bradley1, P J Yaworsky, F S Walsh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425412     DOI: 10.1007/s00018-008-8077-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


× No keyword cloud information.
  31 in total

1.  Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action.

Authors:  Melissa Braga; Shalender Bhasin; Ravi Jasuja; Shehla Pervin; Rajan Singh
Journal:  Mol Cell Endocrinol       Date:  2011-11-25       Impact factor: 4.102

2.  METABOLIC FUNCTIONS OF MYOSTATIN AND GDF11.

Authors:  Alexandra C McPherron
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2010-12

Review 3.  Osteosarcopenia: where bone, muscle, and fat collide.

Authors:  H P Hirschfeld; R Kinsella; G Duque
Journal:  Osteoporos Int       Date:  2017-07-22       Impact factor: 4.507

Review 4.  [Fibroblastic modulators of bone destruction].

Authors:  B Dankbar; T Pap
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

5.  Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.

Authors:  James R Apgar; Michelle Mader; Rita Agostinelli; Susan Benard; Peter Bialek; Mark Johnson; Yijie Gao; Mark Krebs; Jane Owens; Kevin Parris; Michael St Andre; Kris Svenson; Carl Morris; Lioudmila Tchistiakova
Journal:  MAbs       Date:  2016-09-13       Impact factor: 5.857

6.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

Review 7.  Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle.

Authors:  Mark Romanick; Ladora V Thompson; Holly M Brown-Borg
Journal:  Biochim Biophys Acta       Date:  2013-03-20

8.  Myostatin stimulates, not inihibits, C2C12 myoblast proliferation.

Authors:  Buel D Rodgers; Benjamin D Wiedeback; Knut E Hoversten; Melissa F Jackson; Ryan G Walker; Thomas B Thompson
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

9.  The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.

Authors:  Jennifer N Cash; Carlis A Rejon; Alexandra C McPherron; Daniel J Bernard; Thomas B Thompson
Journal:  EMBO J       Date:  2009-07-30       Impact factor: 11.598

Review 10.  Sarcopenia: etiology, clinical consequences, intervention, and assessment.

Authors:  T Lang; T Streeper; P Cawthon; K Baldwin; D R Taaffe; T B Harris
Journal:  Osteoporos Int       Date:  2009-09-25       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.